Search Results

David S. Rosenbloom

David S. Rosenbloom is executive vice president and general counsel. Rosenbloom joined Baxter in 2022 from McDermott Will & Emery, where he served as a partner for 24 years and global head of the Litigation Practice Group from 2017-2022. Prior to McDermott, he served for eight years in the U.S. Attorney’s Office for the Northern District of Illinois.

Floseal Hemostatic Matrix

Floseal is an effective adjunct hemostatic agent proven in a wide-range of bleeding scenarios1 with a proprietary combination of two independent hemostatic agents.1, 2

Tisseel [Fibrin Sealant]

Tisseel is a fibrin sealant with a proven history of clinical safety and efficacy that surgeons rely on for use as an adjunct to hemostasis.

Numeta G13E

Numeta G13E 300 mL is the only triple-chamber, ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants (less than 37 weeks gestation age) who are at high risk for infection and malnutrition5 in the early hours and days of their lives.

HDx Enabled by Theranova

HDx enabled by Theranova is a new dialysis therapy we are pioneering for patients with end-stage renal disease. The Theranova dialyzer features an innovative membrane, which provides an expanded hemodialysis therapy (HDx).

​Jeanne Mason, Ph.D.

Jeanne Mason, Ph.D. is executive vice president and chief human resources officer.

​Stephen N. Oesterle, M.D.

Stephen N. Oesterle, M.D. has served as a director of Baxter since February 2017.

​Cathy R. Smith

Cathy R. Smith has served as a director of Baxter since July 2017.

​Stacey Eisen

Stacey Eisen is senior vice president, Chief Communications Officer and Corporate Marketing, and president, Baxter Foundation.

Reazur (​Reaz) Rasul

Reazur (​Reaz) Rasul is executive vice president and group president, Healthcare Systems & Technologies. He was appointed to his role leading Healthcare Systems & Technologies in 2023 after serving as president of Front Line Care since 2022. Prior to that, Rasul served as general manager for the Acute Therapies & Medication Delivery businesses. He joined Baxter in 2017.